RUOResearch Use Only · Not FDA-cleared

Cardiovascular
Chain Report

CAD polygenic risk → LDL genetic burden → SLCO1B1 statin selection. Three connected panels, one integrated clinical story. The cardiovascular report no competitor offers — and the one your cardiologist needs.

⚠ Research Use Only. Not FDA-cleared or approved. Not intended to diagnose, treat, cure, or prevent any disease. Always discuss findings with a licensed healthcare provider.

📄
Download a sample report

See a fully rendered example — real RSIDs, peer-reviewed citations, and clinical action guidance — before you commit.

↓ Download sample
Key variants

RSIDs analyzed in this panel

Representative variants. Full report includes all associated loci with genotyped values, effect sizes, and clinical interpretation.

rs4977574G/G
ANRIL/9p21.3 · strongest common CAD locus
Risk allele · OR=1.25 per allele in CARDIoGRAM
rs11206510C/T
PCSK9 · LDL-C and CAD risk
Elevated PCSK9 activity → raised LDL-C
rs4149056T/C
SLCO1B1 *5 · Statin myopathy (CPIC Level A)
Intermediate · OR=4.5 myopathy with simvastatin
rs3798220C
LPA · Lipoprotein(a) elevation
Lp(a) risk allele — request Lp(a) blood test
Evidence base

Supporting literature

Patel et al. Nature Medicine 2023 (multi-ancestry CAD PRS · n=243,000+). SEARCH Collaborative Group NEJM 2008 (SLCO1B1 rs4149056 · myopathy OR=4.5 heterozygous, OR=17 homozygous). CPIC Statin/SLCO1B1 Guideline v3.0 (Oct 2025). AHA Circulation PRS Scientific Statement 2022.

The clinical chain — why these three panels must connect

Standard clinical workups order a lipid panel and possibly a CAD risk calculator. They rarely genotype SLCO1B1 before prescribing a statin. Yet if your CAD PRS and LDL burden point toward statin therapy, and your SLCO1B1 genotype makes simvastatin specifically dangerous, all three data points must be read together. AuraGen is the only consumer product that connects them in one report.

Who should order this report

This report is particularly valuable if you have a family history of heart disease, have had a lipid panel showing elevated LDL, are being considered for statin therapy, or score in the 70th+ percentile on AuraGen's base cardiovascular assessment. The SLCO1B1 finding alone — which can prevent a dangerous statin prescription — can justify the cost of the entire kit.

⚠ Research Use Only (RUO)

This report is for Research Use Only and is not FDA-cleared, FDA-approved, or CE-IVD certified. Polygenic risk scores and pharmacogenomic findings reflect statistical associations from published peer-reviewed GWAS studies. Results are not diagnostic and do not constitute medical advice. Always consult a licensed physician, genetic counselor, or pharmacist before acting on any finding. © 2026 AuraGen Wellness · auragenwellness.com

✦ AuraGen Exclusive · Add-On
$129
Instant unlock · no new kit required
  • CAD PRS — CARDIoGRAMplusC4D + UK Biobank + Million Veterans Program model
  • LDL-C polygenic burden — PCSK9, LDLR, APOB, HMGCR pathway variants
  • SLCO1B1 rs4149056 — CPIC Level A statin myopathy risk (OR=4.5 heterozygous)
  • APOE ε2/ε3/ε4 haplotype — lipid metabolism and cardiovascular context
  • LPA rs3798220 — Lp(a) elevation risk (often missed in standard clinical panels)
  • Specific statin recommendation: rosuvastatin or pravastatin over simvastatin
Unlock this panel →↓ Download sample report

⚠ Research Use Only · Not FDA cleared